Mologic is Dedicated to the Elimination of Neglected Diseases

Rapid Diagnostics for Epidemics are Critical for Surveillance, Outbreak Response, and to Accelerate Elimination Efforts. Mologic have created a technology platform and manufacturing suite that can be applied readily and responsively to outbreak-prone and emerging epidemics. Rapid diagnostics play an essential role for epidemic control and surveillance, particularly in the absence of an effective vaccine or therapy.

Since 2018, Mologic has increased its focus on epidemics and neglected diseases now addressing 14 Targets, supported by the Bill & Melinda Gates Foundation, the Wellcome Trust, the UK government, and the Foundation for Innovative New Diagnostics (FIND).

To ensure access and scale for emergency response, Mologic has committed to ensure all its products are made available at cost to Gavi-eligible countries.

In 2015, the Gates Foundation approached Mologic to create the Centre for Advanced Rapid Diagnostics (CARD). CARD was set up with a $5m grant to redefine lateral flow technology and augment its performance to new heights. BMGF set a target of detecting 1pg/ml of HIV or malaria protein using a $1 visually read diagnostic test that could be deployed at the last mile. This represented a 1,000 improvement on previous technology — but without sophisticated set up, instruments, highly trained staff and electricity. This was achieved in 2018 and a subsequent reinvestment of approx $7m was made to scale the platform.

Product branding:

  • EbolaDx

  • YellowFeverDx

  • DengueDx

  • COVID-19

  • Measles


A rapid test to detect viral antigens early in a fingerprick sample of blood for deployment at the point of need. Ebola RDT is made available at cost to address epidemics in Africa.


Yellow Fever RDT is a rapid test to detect viral antigens early in a fingerprick sample of blood. By detecting outbreaks early, in settings where laboratory capacity is limited, we can support more precise and responsive public health measures and immunisation campaigns.


A dual rapid test to detect viral antigens and IgM and IgG antibodies. By deploying virus like particles in a diagnostic, DengueDx boosts performance and will be the first product manufactured at the diaTROPIX manufacturing facility in Dakar, Senegal.


A rapid test to detect IgM antibodies in 10 minutes. With support from the WHO, we will scale access to the rapid test to support surveillance and reduce reliance on laboratory testing.


A dual rapid test to detect viral antigens in saliva and IgM and IgG antibodies in a fingerprick of blood. The device will be made available rapidly at scale in a self test format to mitigate the effects of the current pandemic.

Interested in Partnership & Licensing Opportunities?

Contact Us